- Page 1 and 2: Value through InnovationCorporate M
- Page 3 and 4: our businesses66 [ prescription med
- Page 9 and 10: perspectives for boehringer ingelhe
- Page 11 and 12: corporate responsibilityperspective
- Page 13 and 14: perspectives for societynadezhda ch
- Page 15 and 16: corporate responsibilityperspective
- Page 17 and 18: corporate responsibilityperspective
- Page 19 and 20: corporate responsibilityperspective
- Page 21 and 22: corporate responsibilityperspective
- Page 23 and 24: corporate responsibilityperspective
- Page 25 and 26: corporate responsibilityperspective
- Page 27 and 28: corporate responsibilityperspective
- Page 29 and 30: corporate responsibilityperspective
- Page 31 and 32: corporate responsibilityperspective
- Page 33 and 34: corporate responsibilityperspective
- Page 35 and 36: corporate responsibilityperspective
- Page 37 and 38: corporate responsibilityperspective
- Page 39 and 40: corporate responsibilityperspective
- Page 41 and 42: esearch & developmentperspectives f
- Page 43 and 44: eckhard burbachretiree (formerly he
- Page 45 and 46: esearch & developmentperspectives f
- Page 47 and 48: esearch & developmentperspectives f
- Page 49 and 50: esearch & developmentperspectives f
- Page 51 and 52: esearch & developmentperspectives f
- Page 53 and 54: esearch & developmentperspectives f
- Page 55 and 56:
esearch & developmentperspectives f
- Page 57 and 58:
esearch & developmentperspectives f
- Page 59 and 60:
esearch & developmentperspectives f
- Page 61 and 62:
esearch & developmentperspectives f
- Page 63 and 64:
esearch & developmentperspectives f
- Page 65 and 66:
esearch & developmentperspectives f
- Page 67 and 68:
esearch our businesses & developmen
- Page 69 and 70:
esearch & developmentperspectives f
- Page 71 and 72:
our businessesperspectives for bett
- Page 73 and 74:
our businessesperspectives for bett
- Page 75 and 76:
our businessesperspectives for bett
- Page 77 and 78:
our businessesperspectives for bett
- Page 79 and 80:
our businessesperspectives for bett
- Page 81 and 82:
our businessesperspectives for bett
- Page 83 and 84:
our businessesperspectives for bett
- Page 85 and 86:
our businessesperspectives for bett
- Page 87 and 88:
our businessesperspectives for bett
- Page 89 and 90:
our businessesperspectives for bett
- Page 91 and 92:
our businessesperspectives for bett
- Page 93 and 94:
our businessesperspectives for bett
- Page 95 and 96:
our businessesperspectives for bett
- Page 97 and 98:
our businessesperspectives for bett
- Page 99 and 100:
our businessesperspectives for bett
- Page 101 and 102:
our businessesperspectives for bett
- Page 103 and 104:
our businessesperspectives for bett
- Page 105 and 106:
our businessesperspectives for bett
- Page 107 and 108:
our businessesperspectives for bett
- Page 109 and 110:
our businessesperspectives for bett
- Page 111 and 112:
our businessesperspectives for bett
- Page 113 and 114:
our businessesperspectives for bett
- Page 115 and 116:
production networkperspectives for
- Page 117 and 118:
perspectives for quality in operati
- Page 119 and 120:
production networkperspectives for
- Page 121 and 122:
production networkperspectives for
- Page 123 and 124:
production networkperspectives for
- Page 125 and 126:
esearch our markets& developmentper
- Page 127 and 128:
esearch & developmentperspectives f
- Page 129 and 130:
our marketsperspectives for establi
- Page 131 and 132:
our marketsperspectives for establi
- Page 133 and 134:
our marketsperspectives for establi
- Page 135 and 136:
our marketsperspectives for establi
- Page 137 and 138:
our marketsperspectives for establi
- Page 139 and 140:
www.boehringer-ingelheim.comannualr
- Page 141 and 142:
usiness year 2012contentour company
- Page 143 and 144:
Boehringer Ingelheim groupFINANCIAL
- Page 145 and 146:
THE SHAREHOLDERS’PERSPECTIVEchris
- Page 147 and 148:
Core business secures new growth in
- Page 149 and 150:
KEY ASPECTS 2012andreas barner, wol
- Page 151 and 152:
We are satisfied with this result,
- Page 153 and 154:
Research with passionIn 2012, we em
- Page 155 and 156:
Our goals will be achieved jointly
- Page 157 and 158:
18Boehringer Ingelheim annual repor
- Page 159 and 160:
GROUP MANAGEMENT REPORT 2012BUSINES
- Page 161 and 162:
Business at Boehringer IngelheimIn
- Page 163 and 164:
ingredients for clinical trials, an
- Page 165 and 166:
With regard to the test substance n
- Page 167 and 168:
products for industrial customers c
- Page 169 and 170:
Employee reportingAs in the previou
- Page 171 and 172:
positive development of new, innova
- Page 173 and 174:
oped positively. The most important
- Page 175 and 176:
In the long term, in addition to th
- Page 177 and 178:
iological medicines. This gives us
- Page 179 and 180:
OVERVIEW OF THE MAJOR CONSOLIDATED
- Page 181 and 182:
C. H. Boehringer Sohn AG & Co. KG,
- Page 183 and 184:
C. H. Boehringer Sohn AG & Co. KG,
- Page 185 and 186:
C. H. Boehringer Sohn AG & Co. KG,
- Page 187 and 188:
1.4 Currency translationAssets and
- Page 189 and 190:
Inventories are valued loss-free, i
- Page 191 and 192:
3 NOTES TO THE CONSOLIDATED BALANCE
- Page 193 and 194:
3.3 Financial assets(in millions of
- Page 195 and 196:
In addition to local biometric data
- Page 197 and 198:
4 NOTES TO THE CONSOLIDATED PROFIT
- Page 199 and 200:
4.8 Holding income(in millions of E
- Page 201 and 202:
The purpose of the lease agreements
- Page 203 and 204:
January to December 2015:Net cash f
- Page 205 and 206:
AUDITOR’S REPORTWe have audited t
- Page 207 and 208:
68Boehringer Ingelheim annual repor
- Page 209 and 210:
Respiratory diseasesChronic obstruc
- Page 211 and 212:
Diseases of the central nervous sys
- Page 213 and 214:
Cardiovascular diseasesCardiovascul
- Page 215 and 216:
Cardiovascular diseases (continued)
- Page 217 and 218:
Metabolic diseasesDiabetesType 2 di
- Page 219 and 220:
Cough and coldmucosolvan® (ambroxo
- Page 221 and 222:
Gastrointestinal diseasesIn our gas
- Page 223 and 224:
Vitamins and supplementspharmaton®
- Page 225 and 226:
Leg vein healthUnder the brand name
- Page 227 and 228:
Food producing animals - swineInfec
- Page 229 and 230:
Food producing animals - cattleMast
- Page 231 and 232:
Food producing animals - cattle (co
- Page 233 and 234:
Companion animals - small animalsTh
- Page 235 and 236:
C. H. Boehringer Sohn AG & Co. KG,
- Page 237 and 238:
IF YOU HAVE ANY QUERIES OR COMMENTS